Australia's most trusted
source of pharma news
Friday, 14 February 2025
Posted 14 August 2024 AM
GSK is actively building its first Australian Haematology Team as it pushes forward with plans to introduce at least one new therapy for Australian patients impacted by blood-related cancers.
Recruitment is already underway for relevant medical and commercial personnel and the company's JAK inhibitor Omjjara, for myelofibrosis with moderate to severe anaemia, is already lined up for consideration at the PBAC's November meeting.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.